作者
Laura V Cooper, Tesfaye B Erbeto, Abba A Danzomo, Hamisu W Abdullahi, Kofi Boateng, Usman S Adamu, Faisal Shuaib, Ndoutabe Modjirom, Elizabeth J Gray, Ananda S Bandyopadhyay, Simona Zipursky, Samuel O Okiror, Nicholas C Grassly, Isobel M Blake
发表日期
2024/4/1
期刊
The Lancet Infectious Diseases
卷号
24
期号
4
页码范围
427-436
出版商
Elsevier
简介
Background
Between 2018 and 2022, Nigeria experienced continuous transmission of circulating vaccine-derived type 2 poliovirus (cVDPV2), with 526 cases of cVDPV2 poliomyelitis detected in total and approximately 180 million doses of monovalent type 2 oral poliovirus vaccine (mOPV2) and 450 million doses of novel type 2 oral poliovirus vaccine (nOPV2) delivered in outbreak response campaigns. Inactivated poliovirus vaccine (IPV) was introduced into routine immunisation in 2015, with a second dose added in 2021. We aimed to estimate the effectiveness of nOPV2 against cVDPV2 paralysis and compare nOPV2 effectiveness with that of mOPV2 and IPV.
Methods
In this retrospective case-control study, we used acute flaccid paralysis (AFP) surveillance data in Nigeria from Jan 1, 2017, to Dec 31, 2022, using age-matched, onset-matched, and location-matched cVDPV2-negative AFP cases as test-negative …
学术搜索中的文章
LV Cooper, TB Erbeto, AA Danzomo, HW Abdullahi… - The Lancet Infectious Diseases, 2024